drugset / Trial / NCT01940926
68Ga-BNOTA-PRGD2 PET/CT in Patients With Rheumatoid Arthritis
NaSingle-groupOpen-labelDiagnostic
Summary
This is an open-label positron emission tomography/computed tomography ( PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-BNOTA-PRGD2 in rheumatoid arthritis (RA) patients. A single dose of nearly 111 MBq 68Ga-BNOTA-PRGD2 (≤ 40 µg BNOTA-PRGD2) will be intravenously injected into patients with RA. Visual and semiquantitative method will be used to assess the PET/CT images. Whole body 18F-FDG PET/CT will be performed for comparison.
Timeline
- Start
- 2012-02
- Primary completion
- 2017-11
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-BNOTA-PRGD2 | Diagnostic / imaging agent | 111 mbq | Intravenous |